Promolate

Promolate

SCHEMBL1813845

CC(C)(Oc1ccccc1)C(=O)OCCN1CCOCC1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
PKM P14618 1/20 0.50
CYP2C19 P33261 1/20 0.50
PRCP P42785 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
TACR2 P21452 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
BCHE P06276 1/20 0.48
KDM4E B2RXH2 1/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20066468 0.78 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1CYP1A2CYP3A4
SCHEMBL1529096 0.78 ATM (0.52) ALDH1A1KMT2AMEN1CYP1A2CYP3A4
SCHEMBL2734500 0.76 ATM (0.50) ALDH1A1KMT2AL3MBTL1BCHEKDM4E
SCHEMBL15392656 0.75 KDM4E (0.50) ALDH1A1KMT2AMEN1TACR2BCHE
SCHEMBL501720 0.74 ATM (0.76) ALDH1A1KMT2AMEN1CYP1A2CYP3A4
SCHEMBL23871040 0.74 ATM (0.48) ALDH1A1KMT2AMEN1L3MBTL1BCHE
SCHEMBL12422483 0.74 ATM (0.48) ALDH1A1KMT2AMEN1L3MBTL1BCHE
SCHEMBL14369843 0.73 ATM (0.74) ALDH1A1KMT2AMEN1CYP1A2CYP3A4
SCHEMBL5350446 0.73 ATM (0.74) ALDH1A1KMT2AMEN1CYP1A2CYP3A4
SCHEMBL26785014 0.73 ATM (0.48) ALDH1A1KMT2AMEN1L3MBTL1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US claimed
US-20240131017-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-25 US claimed
US-20240115562-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-11 US claimed
CN-107929743-A Treat the high penetrating power prodrugs composition and medical composition of pulmonary disease 苏州泰飞尔医药有限公司 2018-04-20 CN claimed
CN-107913381-A A kind of Chinese and Western compound medicine and preparation method for treating adverse reaction after intravertebral anesthesia 张翠环 2018-04-17 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
CN-104540504-A High penetration prodrug compositions and pharmaceutical compositions for treating pulmonary diseases TECHFIELDS PHARMA CO LTD 2015-04-22 CN claimed
EP-2849738-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS Techfields Pharma Co., Ltd. (CN) 2015-03-25 EP claimed
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS PREMIER RESEARCH INTERNATIONAL, LLC 2015-03-12 US claimed
CN-101366699-B Novel lipid composition aerosol for the controlled release of pharmaceutically active ingredients UNIV HONG KONG BAPTIST 2014-04-16 CN claimed
WO-2013170655-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2013-11-21 WO claimed
US-20090047336-A1 NOVEL FORMULATION OF DEHYDRATED LIPID VESICLES FOR CONTROLLED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT VIA INHALATION HONG KONG BAPTIST UNIVERSITY (CN) 2009-02-19 US claimed
CN-101366699-A Novel liposomal aerosol for the controlled release of pharmaceutically active ingredients UNIV HONG KONG BAPTIST (HK) 2009-02-18 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US disclosed
US-20240131017-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-25 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH ALDH1A1 1724/4885KMT2A 3535/4885MEN1 2172/4885
US-20240115562-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH ALDH1A1 1724/4885KMT2A 3535/4885MEN1 2172/4885
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH ALDH1A1 1724/4885KMT2A 3535/4885MEN1 2172/4885
US-20240131017-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH ALDH1A1 1724/4885KMT2A 3535/4885MEN1 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.